Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation

Completed · Phase 4

Conditions studied: Atrial Fibrillation, Atrial Flutter

In brief

The primary objective of the study is to reduce hospital admission and decrease time to disposition through establishing an effective treatment protocol for AF and Atrial Flutter in the Emergency Department of Spectrum Health Lakeland. Secondary outcome is to measure if oral diltiazem is an effective HR controlling agent in AF RVR and Flutter.

Key facts

Study ID

NCT05391893

Run by

Corewell Health South

People needed

444

Starts

2020-06-19

Expected to finish

2023-04-01

Last updated by the study team

2024-12-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Heart rate >125
• Systolic BP>110
• Atrial Fibrillation/Flutter confirmed on ECG.
• Meets observation unit requirements (performs certain ADL's (acts of daily living)
• Age>18.

You may not qualify if…

• Wolf-Parkinson-White syndrome
• ST Elevation Myocardial Infarction
• Pregnant
• Clinical diagnosis of Sepsis,
• Decompensated HF
• allergy to Diltiazem
• provider discretion
• clinical need for cardioversion

Where it is running

• Matthew Hysell — Saint Joseph, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.